BPC-157 vs KPV
Both are gut peptides. One repairs, one calms inflammation. Which problem do you have?
Reviewed by the amino101 editorial team. , first published .
BPC-157 and KPV are the two peptides people reach for with gut complaints, and they are not doing the same job. BPC-157 is a 15 amino acid fragment of a protective protein in gastric juice; in rodents it accelerates healing of ulcers, fistulas and colitis by driving new blood vessel growth and cell migration, and it is stable in stomach acid, which is why oral use is plausible. KPV is the last three amino acids of alpha-MSH and carries the hormone's anti-inflammatory effect without its tanning effect. It blocks NF-kB signaling inside cells and is taken up by inflamed intestinal cells through the PepT1 transporter, so oral KPV can act directly on the gut lining. The evidence gap matters: BPC-157 has extensive rodent data and a few small human pilot studies for inflammatory bowel disease; KPV has mouse colitis models and no human trials at all. Neither is approved. Reported oral doses are 250 to 500 mcg for BPC-157 and 500 mcg to 1 mg for KPV. Educational comparison only.
| BPC-157 | KPV | |
|---|---|---|
| Typical dosage | 250 to 500 mcg | 250 to 500 mcg (injectable or nasal); 500 mcg to 1 mg (oral) |
| Frequency | once or twice daily | once or twice daily |
| Route | Subcutaneous, Intramuscular, Oral | Oral, Subcutaneous, Intranasal, Topical |
| Half-life | under 30 minutes in plasma (estimated); tissue effects last much longer | short, likely under 30 minutes in plasma (estimated) |
| Cycle | 4 to 8 weeks | 4 to 8 weeks |
| Research level | Limited research | Preclinical only |
| Human trials | Small pilots | None |
| Status | Investigational, not FDA approved. Prohibited by WADA for athletes. | Investigational, not FDA approved |
| Effects timeline | pain and swelling 3 to 7 days, tendon and muscle function 2 to 4 weeks, gut symptoms 1 to 3 weeks | gut and skin inflammation 1 to 2 weeks, fuller effect 3 to 4 weeks |
Key differences
BPC-157 vs KPV dosage
Dosage patterns reported in research and community protocols, by goal. Taken from each compound page. Not a prescription.
| Goal | Dosage | Frequency |
|---|---|---|
| Acute soft tissue injury | 500 mcg | twice daily |
| Chronic tendon or ligament issue | 250 to 500 mcg | once daily |
| Gut complaints | 250 to 500 mcg | once or twice daily |
| General recovery | 250 mcg | once daily |
| Goal | Dosage | Frequency |
|---|---|---|
| Gut inflammation | 500 mcg to 1 mg | once or twice daily |
| Gut or systemic, injectable | 250 to 500 mcg | once or twice daily |
| Systemic, nasal | 250 to 500 mcg | once or twice daily |
| Skin inflammation | thin layer of low concentration cream | once or twice daily |
Convert any of these to syringe units in the dosage calculator.
Side effects compared
- ▲Injection site redness or mild irritation
- ▲Nausea, more often with oral capsules
- ▲Headache or brief dizziness after a dose
- ▲Transient fatigue or a warm flush shortly after injection
- ▲Rare reports of mood changes, possibly tied to its dopamine and serotonin effects in animals
- ▲Nausea, mostly with injectable use
- ▲Headache
- ▲Injection site irritation
- ▲Stomach upset from oral capsules in some people
- ▲Fatigue reported by a minority of users
Which should you choose?
BPC-157 is the fit when the gut problem is structural: an ulcer, damage after NSAIDs or alcohol, or a lining that needs repair. It also covers tendon and joint issues at the same time, which KPV does not. Reported doses are 250 to 500 mcg once or twice daily, oral for gut use. It has small human pilots behind it, which is more than KPV can claim.
KPV is the fit when the problem is inflammation rather than damage: flares, cramping, post-infection irritation, or an IBD-type pattern. Reported oral doses are 500 mcg to 1 mg on an empty stomach. Be clear that no human trial exists; the entire case is mouse colitis models and a plausible mechanism. It is also the one to add if skin inflammation is part of the picture.
Pick by the nature of the problem. If the gut issue is damage, an ulcer, a lining that needs rebuilding, damage after NSAIDs or alcohol, BPC-157 is the one with the relevant evidence and the longer track record, including small human pilots. If the issue is inflammation, flares, cramping and loose stools that come and go, KPV's mechanism matches better, with the caveat that everything known about it comes from mice. Most people with chronic gut problems end up running both, BPC-157 for repair and KPV for inflammation, usually as oral capsules on an empty stomach so the peptides contact the lining directly. That pairing is covered in the BPC-157 and KPV stack. A note on oral KPV: the published mouse work used nanoparticle formulations to survive digestion, and plain capsules may not deliver the same thing. Neither is a substitute for a diagnosis if symptoms are persistent.
Stacking: Commonly combined for gut protocols: BPC-157 for lining repair and KPV for inflammation, both oral on an empty stomach, often at the same time. Many people run it 4 to 8 weeks and reassess.
BPC-157 is a 15 amino acid fragment of a protective protein found in human gastric juice. People use it for tendon, ligament, muscle and gut healing, and it is one of the most widely used research peptides in the recovery space.
KPV is a three amino acid fragment of alpha-melanocyte stimulating hormone that carries the anti-inflammatory effect of the hormone without its pigmentation effect. It is used for inflammatory bowel symptoms, skin inflammation and general inflammation control.
BPC-157 vs KPV: frequently asked
Can you take BPC-157 and KPV together?
Yes, and that is the standard gut protocol. BPC-157 handles repair and KPV handles inflammation, with no known interaction. Both are usually taken orally on an empty stomach, often at the same time. The BPC-157 and KPV stack covers reported doses and timing.
Which is better for IBS, BPC-157 or KPV?
Neither has a human IBS trial. KPV's anti-inflammatory mechanism fits the inflammatory component and it is the one people report for cramping and flares; BPC-157 is used when the lining itself seems damaged. Many people with IBS symptoms use both, and the reports are anecdotes.
Does KPV work orally?
In mice, yes, especially when packaged in nanoparticles that survive digestion. It is taken up by inflamed intestinal cells via the PepT1 transporter, so the oral route makes mechanistic sense for gut use. Whether plain capsules sold online deliver the same thing is unknown.
Is BPC-157 or KPV safer?
Both have mild reported side effects: nausea, headache, injection site irritation. BPC-157 has small human pilots and extensive rodent safety data; KPV has no human data of any kind. The theoretical concerns differ: BPC-157 promotes blood vessel growth, which raises a question about feeding tumors, and KPV suppresses inflammation broadly, which could blunt a needed immune response during infection.
Is BPC-157 legal in 2026?
It is not approved as a drug anywhere. In April 2026 the FDA removed it from Category 2 of the bulk substances list, and in late July 2026 an advisory committee voted 8 to 6 to recommend adding it to the 503A list; that vote is non-binding and formal rulemaking is pending. It remains WADA prohibited. KPV is not on the WADA list and has no regulatory history at all.
Related reading
Soft tissue and tendon injury recovery
Skin, scar and post-procedure healing
Healing with inflammation and gut support
Gut lining repair and inflammation control
Which healing peptide should you start with, and do you need both?
Dosage
Sources
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review). Current Pharmaceutical Design, 2011
- Oral delivery of KPV nanoparticles alleviates ulcerative colitis in mice. Molecular Therapy, 2015
- Anti-inflammatory peptide KPV is transported by PepT1 into intestinal epithelial cells. Gastroenterology, 2008